



JUL 2 2003

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Randall E. Berglund, General Counsel  
Sybaritic, Inc.  
9220 James Avenue South  
Minneapolis, Minnesota 55431

Re: K024307

Trade/Device Name: Dermosonic Non-Invasive Subdermal Therapy System  
Regulation Number: 21 CFR 890.5300, 21 CFR 890.5660  
Regulation Name: diathermy, ultrasonic; massager, therapeutic  
Regulatory Class: Class II, Class I  
Product Code: IMI, ISA  
Dated: April 1, 2003  
Received: April 3, 2003

Dear Mr. Berglund:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

Page 2 – Mr. Ronald E. Berglund

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

*for Mark M. Mather*

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Statement of Indications for Use

510(k) Number: K024307

Device Name: Dermosonic Non-Invasive Subdermal Therapy System

Indications for use include the following:


a. Therapeutic Massager:

- i. Provides temporary relief of minor muscle aches and pains
- ii. Relieves muscle spasms
- iii. Temporarily improves local blood circulation
- iv. Temporarily reduces the appearance of cellulite

b. Ultrasonic Diathermy :

- i. Relief of pain
- ii. Muscle spasms
- iii. Joint contractures
- iv. NOT for the treatment of malignancies

(PLEASE DO NOT WRITE BELOW THIS LINE—CONTINUE ON ANOTHER PAGE  
IF NEEDED)

  
(Division Sign-Off)  
Division of General, Restorative  
and Neurological Devices

Concurrence of CDRH, Office of Device Evaluation (ODE)

\_\_\_\_\_  
(Division Sign-Off)  
Division of General Restorative  
Devices  
510(k) Number: \_\_\_\_\_

510(k) Number K024307  
Prescription Use \_\_\_\_\_ OR Over-the-Counter Use \_\_\_\_\_

(Per 21 CFR 801.109)